Skip to main content
Terug
BMRN logo

BioMarin Pharmaceutical Inc.

Datakwaliteit: 100%
BMRN
NASDAQ Healthcare Biotechnology
€ 55,59
▲ € 1,50 (2,77%)
Marktkapitalisatie: 10,69B
Dagbereik
€ 54,61 € 55,73
52-Weeksbereik
€ 50,76 € 73,18
Volume
1.947.351
50D / 200D Gem.
€ 58,63 / € 56,59
Vorige Slotkoers
€ 54,09

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 30,6 0,2
P/B 1,8 3,0
ROE % 5,9 3,6
Net Margin % 10,8 3,8
Rev Growth 5Y % 14,9 9,9
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 86,60 +55.8%
Low: € 60,00 High: € 105,00
Forward K/W
12,86
Forward WPA
€ 4,32
WPA Groei (sch.)
+0,0%
Omzet Sch.
3,62B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 8,40
€ 7,98 – € 8,82
 5,08B 6
FY2029 € 7,57
€ 7,19 – € 7,96
 4,79B 6
FY2028 € 6,76
€ 4,90 – € 9,01
 4,42B 8

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-23 € 0,17 € 0,46 +171,5%
2025-10-27 -€ 0,15 € 0,12 +180,0%
2025-08-04 € 0,86 € 1,44 +67,2%
2025-05-01 € 0,94 € 1,13 +20,2%
2025-02-19 € 0,54 € 0,92 +70,4%
2024-10-29 € 0,78 € 0,91 +16,7%
2024-08-05 € 0,36 € 0,96 +168,3%
2024-04-24 € 0,31 € 0,71 +127,7%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 14,93% annually over 5 years — strong growth
Earnings declined -18,26% over the past year
Debt/Equity of 0,11 — conservative balance sheet
Generating 724,96M in free cash flow
P/E of 30,64 — premium valuation
Cash machine — converts 207,78% of earnings into free cash flow

Groei

Revenue Growth (5Y)
14,93%
Revenue (1Y)12,87%
Earnings (1Y)-18,26%
FCF Growth (3Y)240,39%

Kwaliteit

Return on Equity
5,94%
ROIC5,95%
Net Margin10,83%
Op. Margin16,56%

Veiligheid

Debt / Equity
0,11
Current Ratio5,21
Interest Coverage48,95

Waardering

P/E Ratio
30,64
Forward P/E12,86
P/B Ratio1,76
EV/EBITDA18,79
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12,87% Revenue Growth (3Y) 15,39%
Earnings Growth (1Y) -18,26% Earnings Growth (3Y) 44,26%
Revenue Growth (5Y) 14,93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,22B Net Income (TTM) 348,90M
ROE 5,94% ROA 4,59%
Gross Margin 77,13% Operating Margin 16,56%
Net Margin 10,83% Free Cash Flow (TTM) 724,96M
ROIC 5,95% FCF Growth (3Y) 240,39%
Safety
Debt / Equity 0,11 Current Ratio 5,21
Interest Coverage 48,95
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 30,64 Forward P/E 12,86
P/B Ratio 1,76 P/S Ratio 3,32
PEG Ratio -1,71 Forward PEG N/A
EV/EBITDA 18,79 Fwd EV/EBITDA 20,23
Forward P/S 2,96 Fwd Earnings Yield 7,78%
FCF Yield 6,78%
Market Cap 10,69B Enterprise Value 10,02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,22B 2,85B 2,42B 2,10B 1,85B
Net Income 348,90M 426,86M 167,65M 141,56M -64,08M
EPS (Diluted) 1,80 2,21 0,88 0,75 -0,35
Gross Profit 2,48B 2,27B 1,89B 1,59B 1,38B
Operating Income 533,48M 484,21M 185,77M 160,97M -82,34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,59B 6,99B 6,84B 6,38B 6,00B
Total Liabilities 1,51B 1,33B 1,89B 1,77B 1,74B
Shareholders' Equity 6,09B 5,66B 4,95B 4,60B 4,27B
Total Debt 642,87M 649,47M 1,10B 1,09B 1,09B
Cash & Equivalents 1,31B 942,84M 755,13M 724,53M 587,28M
Current Assets 3,95B 3,23B 2,96B 2,75B 2,27B
Current Liabilities 759,03M 606,99M 1,18B 588,88M 546,50M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#697 of 1049
37

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026